biotech / news / / Seeking Alpha
Pfizer remains a high-conviction, undervalued Strong Buy with a robust pipeline and aggressive growth in oncology and obesity platforms.
Pfizer reaffirmed its 2026 revenue guidance of $59.5–$62.5 billion and EPS of $2.8–$3.
KEY POINTS
- Management is aggressively onshoring high-margin production to combat loss-of-exclusivity headwinds.
- Pfizer is prioritizing cost-cutting measures to expand operating margins through 2027.
- Current valuation is 8.13x P/E and 6.4% dividend yield, outpacing industry peers.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →